Inovio Pharmaceuticals, Inc. (NASDAQ:INO) Receives Consensus Rating of “Hold” from Analysts

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) has been given a consensus recommendation of “Hold” by the eight brokerages that are covering the stock, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and four have issued a buy rating on the company. The average 12-month target price among brokerages that have issued ratings on the stock in the last year is $6.75.

A number of research firms recently commented on INO. Oppenheimer reiterated an “outperform” rating on shares of Inovio Pharmaceuticals in a research note on Friday, March 13th. Wall Street Zen upgraded Inovio Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, March 14th. Finally, Weiss Ratings downgraded Inovio Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Wednesday, May 6th.

Hedge Funds Weigh In On Inovio Pharmaceuticals

Hedge funds have recently bought and sold shares of the company. Boxer Capital Management LLC acquired a new position in Inovio Pharmaceuticals in the third quarter worth about $5,382,000. Marshall Wace LLP acquired a new position in Inovio Pharmaceuticals in the fourth quarter valued at approximately $143,000. AQR Capital Management LLC acquired a new position in Inovio Pharmaceuticals in the first quarter valued at approximately $120,000. Hudson Bay Capital Management LP acquired a new position in Inovio Pharmaceuticals in the fourth quarter valued at approximately $88,000. Finally, Jane Street Group LLC boosted its stake in Inovio Pharmaceuticals by 221.2% in the second quarter. Jane Street Group LLC now owns 39,683 shares of the biopharmaceutical company’s stock valued at $81,000 after acquiring an additional 27,329 shares during the period. 26.79% of the stock is currently owned by institutional investors and hedge funds.

Inovio Pharmaceuticals Stock Performance

NASDAQ:INO opened at $1.43 on Tuesday. The company has a market capitalization of $99.30 million, a price-to-earnings ratio of -0.85 and a beta of 1.43. Inovio Pharmaceuticals has a one year low of $1.03 and a one year high of $2.98. The stock has a 50-day simple moving average of $1.41 and a 200 day simple moving average of $1.73.

Inovio Pharmaceuticals (NASDAQ:INO) last posted its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported $0.31 EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.68. On average, equities research analysts forecast that Inovio Pharmaceuticals will post -1.06 EPS for the current fiscal year.

Inovio Pharmaceuticals Company Profile

Inovio Pharmaceuticals is a biotechnology company focused on the discovery, development and commercialization of DNA-based immunotherapies and vaccines aimed at treating and preventing infectious diseases and cancers. The company leverages proprietary technologies to design synthetic DNA sequences that encode antigens capable of eliciting targeted immune responses. Inovio’s business activities span early research through clinical development, with a primary emphasis on advancing candidates against viral pathogens such as SARS-CoV-2, human papillomavirus (HPV), HIV, Ebola, Zika and other emerging threats.

Central to Inovio’s platform is its SynCon® technology, which constructs optimized DNA plasmids for broad antigen coverage, and the Cellectra® electroporation device, designed to enhance cellular uptake and expression of DNA vaccines.